In this article, we will be taking a look at the Top 5 Stock Picks of John Zaro’s Bourgeon Capital. To read our detailed analysis of John Zaro’s profile, investment strategy, risk/reward, and 13F holdings, you can go to Top 10 Stock Picks of John Zaro’s Bourgeon Capital.
5. Danaher Corporation (NYSE:DHR)
Bourgeon Capital’s Stake Value: $12,318,000
Percentage of Bourgeon Capital’s 13F Portfolio: 3.25%
Number of Hedge Fund Holders: 82
Danaher Corporation (NYSE:DHR) is a global science and technology company providing products and services across life sciences, diagnostics, environmental and applied sectors through more than 20 operating companies. It has operations in more than 60 countries.
Danaher Corporation (NYSE:DHR) is among the top 5 companies on the list of Bourgeon Capital’s holdings with the investment company owning 48,587 shares making up 3.25% of its 13F portfolio. Bourgeon Capital’s stake increased by 1% in Q2 2020, compared to the previous quarter.
In July, Danaher Corporation (NYSE:DHR) released the financial results for Q2 2022 ended July 1, 2022. Its revenue increased by 7.5% y-o-y to $7.8 billion, while its net income declined by 1.5% y-o-y to $1.7 billion, for the three months. The normalized EPS for the quarter was recorded at $2.76, beating the consensus by $0.42.
Last month, analysts at RBC Capital, Baird, and Barclays raised the price target for Danaher Corporation (NYSE:DHR) shares, while UBS analyst Elizabeth Garcia initiated coverage of the stock with a ‘Buy’ rating.
As of Q2 2022, 82 hedge funds tracked by Insider Monkey were long Danaher Corporation (NYSE:DHR).
4. Honeywell International Inc. (NYSE:HON)
Bourgeon Capital’s Stake Value: $13,085,000
Percentage of Bourgeon Capital’s 13F Portfolio: 3.46%
Number of Hedge Fund Holders: 42
Charlotte, North Carolina-based Honeywell International Inc. (NYSE:HON) is a multinational conglomerate with a focus on providing solutions across aerospace, building technologies, performance materials & technologies, and safety & productivity solutions.
John Zaro’s Bourgeon Capital holds 75,281 shares of Honeywell International Inc. (NYSE:HON), representing 3.46% of the 13F Portfolio of the hedge fund. The number of shares held by Bourgeon Capital has increased by 65% since the beginning of this year.
Honeywell International Inc. (NYSE:HON) released the financial results for Q2 2022. Its total revenue increased by 2% y-o-y to $8.95 billion, while its net income declined by 13% y-o-y to $1.3 billion, for three months ended June 30, 2022. It reported a normalized EPS of $2.10, beating the consensus by $0.07.
Following the earnings release, Citi analyst Andrew Kaplowitz raised the price target for Honeywell shares to $222 from $211 and maintained a ‘Buy’ rating.
As of Q2 2022, 42 hedge funds tracked by Insider Monkey held shares of Honeywell International Inc. (NYSE:HON), valued at $1 billion.
3. Jacobs Engineering Group Inc. (NYSE:J)
Bourgeon Capital’s Stake Value: $14,076,000
Percentage of Bourgeon Capital’s 13F Portfolio: 3.72%
Number of Hedge Fund Holders: 28
Founded in 1947, Dallas, Texas-based Jacobs Engineering Group Inc. (NYSE:J) is a global professional services provider focused on providing consulting, technical, scientific and project delivery services for the government and private sector. With operations in more than 50 countries, its focus areas include advanced manufacturing, cities and places, energy and environment, health and life sciences, infrastructure, security, and space.
Bourgeon Capital holds 110,719 shares of Jacobs Engineering Group Inc. (NYSE:J), making up for 3.72% of the hedge fund’s 13F portfolio and ranks #3 based on the portfolio weight. Bourgeon Capital’s stake increased by 1% in 2Q 2022, compared to the previous quarter.
In first week of August, Jacobs Engineering Group Inc. (NYSE:J) released the financial results for Q3 2022 ended July 1, 2022. Its revenue increased by 7% y-o-y to $3.8 billion, while its net income increased by 19% y-o-y to $ 196 million. It reported a normalized EPS of $1.86, beating consensus by $0.06.
Following the earnings release, Citi analyst Andrew Kaplowitz and Credit Suisse analyst Jamie Cook lowered the price target on Jacobs to $151 and $154, respectively, maintaining their respective ‘Buy’ and ‘Outperform’ rating on the shares.
According to Insider Monkey data on almost 900 hedge funds, 28 hedge funds held shares of Jacobs Engineering Group Inc. (NYSE:J) valued at $947.2 million.
2. JPMorgan Chase & Co. (NYSE:JPM)
Bourgeon Capital’s Stake Value: $14,196,000
Percentage of Bourgeon Capital’s 13F Portfolio: 3.75%
Number of Hedge Fund Holders: 104
JPMorgan Chase & Co. (NYSE:JPM) is one of the leading financial institutions in the US with a history dating back over 200 years. It provides services including investment banking, financial services for consumers and small business, commercial banking, financial transactions processing and asset management. JPMorgan Chase & Co. (NYSE:JPM) has over $2.6 trillion in client assets under management and serves clients across more than 100 countries.
John Zaro’s Bourgeon Capital holds 126,065 shares of JPMorgan Chase & Co. (NYSE:JPM), making up for 3.75% of the hedge fund’s 13F portfolio. Bourgeon Capital’s stake increased by 4% in Q2 2022, compared to the previous quarter.
JPMorgan Chase & Co. (NYSE:JPM) released its quarterly results for Q2 2022 in July. Its net revenue increased by 1% y-o-y to $30.7 billion, while net income decreased by 28% y-o-y to $8.6 billion, for the quarter ended June 30, 2022. It reported a normalized EPS of $2.76, missing the consensus by $0.14. Last month, Berenberg analyst Peter Richardson upgraded JPMorgan Chase & Co. (NYSE:JPM) to ‘Hold’ from ‘Sell’ with an unchanged price target of $120.
As of Q2 2022, 104 hedge funds tracked by Insider Monkey were bullish on JPMorgan Chase & Co. (NYSE:JPM).
1. Merck & Co., Inc. (NYSE:MRK)
Bourgeon Capital’s Stake Value: $15,305,000
Percentage of Bourgeon Capital’s 13F Portfolio: 4.04%
Number of Hedge Fund Holders: 79
Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company with a focus on delivering solutions for oncology, vaccines, infectious diseases, Cardio-metabolic disorders, and Discovery & development. Its product pipeline comprises 83 programs in Phase 2, 30 programs in Phase 3, and 3 programs Under Review, including a COVID19 vaccines.
Bourgeon Capital holds 167,874 shares of Merck & Co., Inc. (NYSE:MRK), accounting for 4.04% of the hedge fund’s 13F portfolio and ranking the stock on #1 on the list of top 5 and 10 stock picks of John Zaro’s Bourgeon Capital. Bourgeon Capital’s stake increased by 1% in Q2 2022, compared to the previous quarter.
In July, Merck & Co., Inc. (NYSE:MRK) released the financial results for Q2 2022. Its revenue increased 28% y-o-y to $14.6 billion, while it reported a net income of $3.9 billion, for three months ended June 30, 2022. It reported a normalized EPS of $1.87, beating analyst consensus by $0.16.
Following the earnings release, Barclays analyst Carter Gould raised the price target on Merck & Co., Inc. (NYSE:MRK) shares to $101 from $97, maintaining an ‘Overweight’ rating for the stock.
Merck & Co., Inc. (NYSE:MRK) ranks high on the list of companies displaying significant interest from hedge funds tracked by Insider Monkey. As of Q2 2022, 79 hedge funds tracked by Insider Monkey held a stake in Merck & Co., Inc. (NYSE:MRK), valued at a total of $6.1 billion.
You can also take a look at the 5 Best Stocks to Invest Your $1000 According to Reddit and Here’s Why Arch Capital Invested in Alphabet (GOOG).
